Safety Study of Once a Day ART and Opiate Substitute.

NCT ID: NCT00324688

Last Updated: 2014-03-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2003-03-31
• Study Completion Date: 2006-06-30

Brief Summary

This study looks at HIV-infected subjects who are on methadone treatment and medicines for HIV.

Detailed Description

Patients with a history of opiate abuse (IVDU) are not only a patient population that is frequently difficult to reach by the healthcare system, but it also exhibits specific problems in HIV-treatment (ART). These patients frequently have a chaotic lifestyle, which makes it difficult to take medications regularly. Amongst the reasons for this are housing difficulties, intoxication and substance abuse.

The introduction of opiate substitution treatment can help to provide some structure and certainty to patients. Even so IVDU patients are often started on ART later than others and have a greater tendency to have treatment interruptions and sub-optimal adherence to ART. The end result can be treatment failure and the development of drug resistance.

There is an unmet medical need for ART regimens that make adherence easier and may be suitable for co-administration with once-daily opiate substitution.

The availability of tenofovir disoproxil fumarate (DF) 300 mg offers new options in the creation of once-daily regimens with reduced potential for drug-drug-interactions. It is believed that it is now possible to construct viable once daily HIV treatment regimens for patients who have either never received prior therapy or who have no history of drug resistance. Tenofovir DF is administered as a single 300 mg tablet once daily with food for the treatment of HIV infection. This once daily dosing schedule of tenofovir DF makes it an attractive option for simplified dosing regimens in many subjects, including methadone-maintained individuals infected with HIV. Because many opiate-maintained subjects are required to have their methadone dosing directly observed in the clinic, there is considerable interest in using directly-observed therapy (DOT) in such subjects. Given that tenofovir is eliminated renally and methadone is predominantly hepatically metabolized, the potential for a pharmacokinetic interaction is low. However, other antiretroviral agents with substantial renal elimination such as didanosine and stavudine have been shown to interact pharmacokinetically with methadone. Thus, it is important to demonstrate that tenofovir DF and methadone can be administered together safely and without concern for a pharmacokinetic interaction and/or alterations in the efficacy, safety, or tolerability of methadone maintenance such that dose modifications would be required. This can also be influenced by the other products in the combination therapy.

HIV/HBV coinfection is a frequent issue in this population (> 20%). Treatment with TDF, which is active against HBV, could help to stabilize the chronic HBV infection, even in cases with Lamivudine-resistance.

Conditions

HIV Infections

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

Viread

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Ages 18 years or older
• Previously documented diagnosis of HIV-1 infection:

• by antibody assay (enzyme immunoassay confirmed by western immunoblot); or
• positive HIV culture; or
• detectable plasma HIV-1-RNA levels by reverse transcriptase polymerase chain reaction (RT-PCR).
• Receiving stable opiate substitution (stable methadone level for ≥ 2 weeks prior to entry into the study) with methadone, levomethadone or buprenorphine
• Either:

• Antiretroviral (ARV) therapy-naïve(*) and with:

• CD4 counts < 351 cells/µL; and/or
• HIV-1 plasma levels >= 30,000 copies/mL (*)less than 3 months of ART for vertical transmission is considered as ARV therapy naïve.
• Or restarting ART after treatment discontinuation with no evidence of prior HIV virological failure (virological failure defined as 2 consecutive measurements 4 weeks apart with viral load of HIV RNA > 400 copies/mL while on ART)
• Or currently receiving stable ART therapy and with virological suppression (< 400 copies/mL), for at least 6 months and:

• suffering from adherence problems because of dosing of current ART; or
• suffering from side effects on the current recorded ART.
• Able to give informed consent
• In the opinion of the investigator is likely to be able to complete the study

Exclusion Criteria

• Need for antiretroviral therapy which is not according to protocol
• Pregnant or breastfeeding women
• Females of childbearing potential not willing to use a barrier method(s) of contraception during heterosexual intercourse during the duration of the study
• Contraindication to use of tenofovir DF 300 mg or another concomitant medication
• Known hypersensitivity to the active component or excipients
• Prior receipt of tenofovir
• Evidence of clinical, genotypic, or phenotypic resistance to any ARV
• History of virological failure while on previously recorded ART regimens (virological failure defined as 2 consecutive measurements 4 weeks apart with viral load of HIV RNA > 400 copies/mL)
• Acute, life-threatening infection or malignancy that needs systemic therapy
• Any clinical laboratory findings obtained during screening that could be a risk factor for the patient during the study:

• Grade 4 increase of any laboratory value
• Grade 3 (> 5-10 upper limit of normal [ULN] increase in transaminases) at the screening visit
• Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with the study requirements.
• Current use of medication that, in the investigator's opinion or sponsor's opinion, will interfere with the study medication
• Participation in other clinical trials
• More than three months of ART treatment for vertical transmission prophylaxis
• Current receipt of adefovir dipivoxil

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Gilead Sciences

INDUSTRY

Sponsor Role: lead

Principal Investigators

Thomas Mertenskoetter

Role: STUDY_DIRECTOR

Gilead Sciences

Locations

Gilead Sciences

Munich, , Germany

Countries

Germany

Other Identifiers

GS-02-1015

Identifier Type: -

Identifier Source: secondary_id

GS-MC-104-1015

Identifier Type: -

Identifier Source: org_study_id